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ABSTRACT
Objectives: Determining the prevalence of multiple cardi-
ometabolic risk (CMR) factors requires clinical and labora-
tory data not readily available to most health-care plans.
We evaluated the ability of a simple model derived from
the National Health and Nutrition Examination Survey
(NHANES) using commonly available demographic infor-
mation to predict prevalence of multiple CMR factors.
Methods: We deﬁned CMR factors according to the
National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) and International Diabetes Feder-
ation (IDF) guidelines for metabolic syndrome classiﬁcation
in both the Atherosclerosis Risk in Communities (ARIC) and
the Framingham Offspring Study (FOS) cohorts. Using
NHANES data, a simple demographic model consisting of
sex, race and ethnicity, smoking status, and the natural log-
arithm of age, generated the coefﬁcients used to predict the
prevalence of multiple CMR factors in ARIC and FOS. Pre-
dicted prevalences were compared with the observed preva-
lences in both cohorts.
Results: The ARIC and FOS cohorts consisted of 11,596
and 3532 subjects with a mean age of 62.6 and 58.8 years,
respectively. The observed proportion of participants with
metabolic syndrome in ARIC was 52.1% and 58.8%
according to the NCEP and IDF deﬁnitions, respectively. In
FOS the observed prevalence was 41.4% and 45.8% using
the NCEP and IDF deﬁnitions. Predicted prevalences of
metabolic syndrome for the NCEP and IDF deﬁnitions,
respectively, were 51.3% and 53.5% in ARIC, and 48.2%
and 51.4% in FOS. Differences between the observed and
predicted prevalences for three of four additional risk fac-
tor sets, including abdominal obesity (AO) alone, AO plus
diabetes, and AO plus diabetes plus dyslipidemia, were
small (between 1 to 7 percentage points) in both cohorts.
The model poorly predicted the prevalence of AO plus
dyslipidemia.
Conclusion: A simple demographic model adequately pre-
dicted the prevalence of CMR factors. The model should
help health-care plans lacking clinical and laboratory data to
estimate prevalence of CMR factors in their populations.
Future studies need to evaluate the inﬂuence of race, sex, and
ethnicity on prevalence of these risk factors in various
settings.
Keywords: Atherosclerosis Risk in Communities Study, body
mass index, diabetes, dyslipidemia, Framingham Offspring
Study, glucose, metabolic syndrome, obesity, prediction
model.
Introduction
Cardiometabolic risk (CMR) factors, including obes-
ity, dyslipidemia, hypertension, and insulin resistance,
are health conditions known to increase the risk of car-
diovascular disease. A major public health concern is
the high prevalence of these risk factors among US
adults, aged 20 years and older. In 2004, the preva-
lence of obesity was estimated to be 32.9% among US
adults, aged 20 to 74 years [1]. Based on the National
Health and Nutrition Examination Survey (NHANES)
III data, the estimated prevalence of dyslipidemia
among US adults aged 20 years and older was 35.6%
[2]. During 1999 to 2002, the estimated prevalence
of hypertension was 28.6% among US adults aged
20 years and older [3]. Insulin resistance, by either evi-
denced impaired fasting glucose (IFG) or diabetes, is
also high. In 2005, the estimated prevalence of total
diabetes was 9.6% among US adults aged 20 years and
older, and 20.9% among US adults aged 60 years and
older [4].
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The population at risk for vascular disease, and
especially for diabetes, includes patients with IFG,
which has an estimated prevalence of 26% in adults
aged 20 years and older [5]. An alarming observation
is that IFG generally increases with age, peaking at
39.1% in the elderly population aged 65 years and
older [5]. This age group is of particular concern
because it is the most rapidly growing population
segment [6] and, in 2004, contained almost 40% of the
diabetic population in the United States [7]. In the US
population, the proportion of diabetics who are eld-
erly is projected to increase to 58% by 2050 [8].
The relationship between each risk factor and car-
diovascular disease is complex, and is complicated fur-
ther by the relationships the risk factors have with each
other. Some researchers suggest that the presence of
multiple CMR factors increases the risk for developing
cardiovascular disease, with relative risks for arterio-
sclerotic cardiovascular disease between 1.4 and 4.3,
depending on vascular outcomes and risk factor burden
[9–17]. Studies demonstrate that non-diabetics with
cardiometabolic risk factors have at least twice the risk
of developing type 2 diabetes as those without cardi-
ometabolic risk factors [18–21]. Finally, as the number
of cardiometabolic risk factors increases, the risk of car-
diovascular disease accelerates in non-diabetics [20].
Whether the presence of multiple CMR factors can
be classiﬁed as a unique syndrome is now a topic of
debate [22–24]. Risk factors associated with various
degrees of morbidity and the development of costly
sequelae are obesity, and perhaps a more reﬁned deﬁ-
nition of increased waist circumference with elevated
triglycerides, low high-density lipoprotein (HDL) cho-
lesterol, elevated fasting glucose, and elevated blood
pressure or hypertension. Whether we consider each
factor alone or in combination, the result is a patient
population at high risk for devastating health conse-
quences if not treated. The joint relationship between
future risk of cardiovascular disease and increases
in weight, glucose, and blood pressure, and lipid
derangements warrants further investigation. At a
minimum these risk factors do appear to cluster and
are associated with signiﬁcant morbidity. A critical
ﬁrst step is raising awareness of the prevalence of these
risk factor in various health-care settings.
Until recently, determining the presence of CMR
clusters required clinical and laboratory data not read-
ily available to most health-care plans. Now Hollen-
beak et al. [submitted] have developed a model and
presented the possibility of accurately predicting the
prevalence of CMR clusters using only simple demo-
graphic data. The research presented below sought to
test whether Hollenbeak’s model could accurately pre-
dict the prevalence of CMR clusters in two large and
diverse observational studies, the Atherosclerosis Risk
in Communities Study (ARIC) and the Framingham
Offspring Study (FOS).
Methods
Data
We used two separate data sets to test the predictive
equations developed by Hollenbeak et al. [submitted],
the ARIC-, and FOS. ARIC, a prospective study of
four community sites in Maryland, Mississippi, Mis-
souri, and North Carolina, was designed to study risk
factors and the natural history of atherosclerosis and
cardiovascular disease among an ethnically diverse
cohort. A cohort of nearly 16,000 was examined at
baseline (1987) and reexamined four times at 3-year
intervals. Examinations included extensive laboratory
tests and anthropometric assessments. In addition to
periodic medical examinations at the center, yearly fol-
low-up phone interviews were conducted by study
staff to update the health status of each participant.
Analyses presented here are restricted to examination
4, which was conducted between 1996 and 1998
(N = 11,596).
Framingham Offspring Study began in 1971 with
the recruitment of 5124 men and women, consisting of
offspring of participants in the original Framingham
Heart Study. FOS participants have completed six
regular physical examinations and surveys of lifestyle
factors (including extensive laboratory tests and
anthropometric examinations) at intervals of 4 to
6 years and have been followed for morbidity and
mortality over that time period. Analyses presented
here are restricted to examination 6, which was con-
ducted between 1996 and 1999 (N = 3532).
We excluded individuals lacking data for any of the
CMR factors of interest, leaving a study sample of
3222 and 11,000 adults in FOS and ARIC, respec-
tively, for analyses.
Deﬁnitions of Risk Factors
Deﬁnitions of the six CMR factor sets are presented in
Table 1. Individuals with cardiovascular comorbidities
were not excluded. The two data sets did not allow for
uniform adherence to the cluster deﬁnitions in two
instances: medications for triglycerides and evidence
of previously diagnosed diabetes. ARIC is currently
developing an indicator variable for antitriglyceride
medications for its public-use data set; this indicator is
available in FOS. For prior diabetes, ARIC provided
age of onset, whereas FOS provided an indicator var-
iable for whether one of two diabetes-diagnosing con-
ditions was met: fasting plasma glucose greater than or
equal to 126 mg/dL or self-report of taking antidiabetes
medications. The risk factor deﬁnitions were applied to
the data sets using the STATA statistical package, version
8.2 (StataCorp, College Station, TX, USA).
Observed and Predicted Prevalence
For each set of CMR factors, we computed an
observed prevalence and 95% conﬁdence interval as a
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simple binomial proportion using the SAS statistical
package (version 9.1) (SAS Institute, Cary, NC, USA).
We used the logistic regression models derived from
the NHANES data set and developed by Hollenbeak
et al. [submitted] to obtain the predicted prevalence of
each of the six sets. Speciﬁcally, we applied the coefﬁ-
cients from those regression models to score the data in
ARIC and FOS, respectively, and produced the pre-
dicted prevalence as the mean of the individual pre-
dicted probabilities. Conﬁdence intervals around the
predicted prevalence point estimates were derived
from a bias-corrected bootstrapping procedure using
1000 replicates. We repeated the procedure to assess
how well the predicted prevalence matched the
observed prevalence in three age strata: <55 years, 55
to 64 years, and >64 years.
Results
Table 2 presents the demographic and clinical charac-
teristics of the two study populations. ARIC partici-
pants were older on average (mean age 62.6 year in
ARIC vs. 58.8 year in FOS) and had a higher percent-
age of women (55.8% vs. 53.1%) than FOS partici-
pants. Also, the distribution of race varied (100%
white in FOS compared with 77% in ARIC) and race
varied ARIC participants had higher mean waist cir-
cumference, body mass index, fasting glucose and trig-
lyceride values, and lower mean HDL and diastolic
blood pressure. The prevalence of most of the CMR
factors under study was higher among ARIC partici-
pants than among those in FOS (Table 3).
Although both systolic and diastolic blood pressure
was higher among FOS participants, more ARIC par-
ticipants were classiﬁed as having elevated blood pres-
sure, having met the criteria because they had received
treatment. Table 4 and Figure 1 show the observed and
predicted prevalence of the six sets of CMR factors in
the two cohorts. The table includes the demographic
inputs for the prediction model (i.e., mean age, pro-
portion of men, smokers, and race) for each cohort.
For the ﬁve risk factor sets other than abdominal obes-
ity (AO) plus dyslipidemia, the differences between the
observed and predicted prevalence range from 0.8% to
6.8%. The predictive ability of the model for the AO
plus dyslipidemia risk factor set is poor in both pop-
ulations (differences of 21.9% and 11.7% in ARIC
and FOS, respectively). For the ﬁve other sets, differ-
ences between the observed and predicted prevalence
in ARIC are within two percentage points for three sets
and just more than ﬁve percentage points for the other
two. In FOS, differences in two risk factor sets are
within two percentage points, and differences for the
other three are within seven percentage points. The
95% conﬁdence intervals derived from the bootstrap-
ping procedures for the predicted prevalence estimates
do not include the observed point prevalence.
The observed and predicted prevalence of the six
sets of CMR factors in three age groups (<55 years,
55–64 years, and >64 years) across the two cohorts are
Table 1 Cardiometabolic risk factor clusters
Metabolic syndrome
NCEP ATP III
Abdominal
obesity (AO) AO + diabetes AO + dyslipidemia
AO + diabetes + 
dyslipidemia Metabolic syndrome IDF [25]
≥3 of the following 
risk factors
High WC High WC +
diabetes
High WC + high
TG or low HDL
High WC + diabetes 
+ high TG or low HDL
High WC + 2 of the other 4 risk 
factors
WC (cm)
Men > 102 Men > 102 Men > 102 Men > 102 Men > 102 Men ≥ 94*
Women > 88 Women > 88 Women > 88 Women > 88 Women > 88 Women ≥ 80*
TG (mg/dL)
≥150 NA NA ≥150 ≥150 ≥150, or on treatment for high 
TG
HDL (mg/dL)
Men < 40 NA NA Men < 40 Men < 40 Men < 40
Women < 50 Women < 50 Women < 50 Women < 50 or on treatment 
for low HDL
BP (mm Hg)
SBP ≥ 130 or
DBP ≥ 85 or
current use of 
antihypertensive 
medication
NA NA NA NA SBP ≥ 130 or DBP ≥ 85 or
current use of antihypertensive
medication (Same as for NCEP)
FPG (mg/dL)
≥100 or use of
diabetes medication
NA ≥126 or use of
diabetes 
medication
NA ≥126 or use of diabetes
medication
≥100 or previously diagnosed 
type 2 diabetes
*For white and African American subjects. Refer to Ford’s article for other ethnic group-speciﬁc thresholds including for Mexican-American subjects [25].
ATP III, Adult Treatment Panel III; BP, blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoprotein; IDF, International Diabetes Fed-
eration; NA, not applicable; NCEP, National Cholesterol Education Program; SBP, systolic blood pressure; TG, triglycerides; WC, waist circumference.
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shown in Table 5 and includes the demographic inputs
for the prediction model (i.e., mean age, and propor-
tion of men, smokers, and race) for each population
subset. The differences between observed and pre-
dicted values are, again, higher in the set including AO
and dyslipidemia. In ARIC, differences between the
observed and predicted prevalence do not vary system-
atically with age group, whereas the prediction model
usually performs better in the 55 to 64 years age range
in FOS compared with the younger (<55) FOS group.
When the AO plus dyslipidemia set is excluded, the
differences between the observed and predicted prev-
alence in ARIC are within ﬁve percentage points for 13
of the 15 sets across the age strata, and the remaining
two are within six percentage points. Differences
between the observed and predicted prevalence are
within ﬁve percentage points in 10 of the 15 sets
(excluding AO plus dyslipidemia) across the age strata
in FOS. In the younger age group (<55 years) in FOS,
differences between the observed and predicted prev-
alence are within 10 percentage points in four sets and
within ﬁve percentage points in two of those.
Discussion
In this study, population characteristics commonly
available to health-care plans predicted the prevalence
of different sets of CMR factors in both the ARIC and
FOS cohorts. The predicted versus observed preva-
lence of metabolic syndrome based on National Cho-
lesterol Education Program (NCEP) criteria were
similar in both cohorts (predicted 51.3% vs. observed
52.1% for ARIC and predicted 48.2% vs. observed
41.1% for FOS). Differences in the demographics
including race between ARIC and FOS resulted in
slightly different proportions in the CMR factor esti-
mates; thus, this simple model performed reasonably
well in both cohorts.
Because of concerns over morbidity related to CMR
factors, estimating their prevalence is of paramount
importance. Recognizing the importance of identifying
Table 2 Demographic and selected clinical characteristics of
the Atherosclerosis Risk in Communities Study (ARIC) and
Framingham Offspring Study (FOS) populations
Characteristic ARIC FOS P-value
N 11,596 3,532
Age (years)
Mean (SD)  62.6 (5.31) 58.8 (9.71) <0.0001
Median  62 58
Sex
Women, n (%) 6,475 (55.8) 1,875 (53.1) 0.004
Men, n (%) 5,121 (44.2) 1,657 (46.9)
Race
African American, n (%) 2,654 (22.9) 0 (0)
White, n (%) 8,942 (77.1) 3,532* (100)
Smoking
Noncurrent, n (%) 9,776 (85.1) 2,992 (84.7) 0.5518
Current, n (%) 1,709 (14.9) 540 (15.3)
Missing  111 0
Blood pressure-systolic (mm Hg)
Mean (SD)  127.8 (19.2) 128.5 (19.3) 0.0547
Median  126 126
Missing  15 2
Blood pressure-diastolic (mm Hg)
Mean (SD)  71.1 (10.4) 75.6 (9.9) <0.0001
Median  71 76
Missing  15 3
Waist circumference (cm)
Mean (SD)  101.9 (14.3) 97.7 (13.6) <0.0001
Median  101.0 97.2
Missing  0 76
Body mass index
Mean (SD)  28.8 (5.6) 28.0 (5.2) <0.0001
Median  28.0 27.2
Missing  38 49
Fasting glucose (mg/dL)
Mean (SD)  111.0 (38.4) 103.9 (27.9) <0.0001
Median  100 97
Missing  96 53
HDL cholesterol (mg/dL)
Mean (SD)  50.0 (16.5) 51.0 (16.2) <0.0001
Median  47 49
Missing  96 62
Triglycerides (mg/dL)
Mean (SD)  143.8 (87.3) 141.7 (133.5) <0.0001
Median  122 117
Missing  96 53
*A race variable was not provided in the FOS public-use data set. The racial com-
position was entered as 100% white in the prediction models.
Figure 1 Observed and predicted prevalence of six cardiometabolic risk
factor sets in (a) Atherosclerosis Risk in Communities Study and (b) Fram-
ingham Offspring Study. AO, abdominal obesity; DL, dyslipidemia; DM,
diabetes; IDF, International Diabetes Federation deﬁnition of metabolic
syndrome; NCEP, National Cholesterol Education Program Adult Treat-
ment Plan III deﬁnition of metabolic syndrome.
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these factors, the NCEP Adult Treatment Plan (ATP)
III published criteria for metabolic syndrome, which
combines these risk factors. The International Diabetes
Federation (IDF) also published guidelines for classi-
fying subjects with this constellation of risk factors,
although the criteria differed in that a person had to
have central obesity as an entry criterion; furthermore,
the IDF deﬁnition included subjects who were treated
for hypertriglyceridemia or low HDL cholesterol. As a
result, these deﬁnitions provide different prevalence
estimates. In NHANES, Ford reported a prevalence of
34.5% using the NCEP deﬁnition and 39% using the
IDF deﬁnition [25]. We found similar differences in
FOS, where the NCEP and IDF deﬁnitions yielded
prevalence estimates of 41.4% and 45.8%, respec-
tively. The prevalence estimates in ARIC were similar
to those for FOS, and estimates were higher with the
IDF deﬁnition compared with the NCEP deﬁnition.
The differences are explained in part by the inclusion
of the treatment variables in the IDF deﬁnition. Also
differences are in part explained by demographic dif-
ferences between the subjects in both databases com-
Table 3 Observed prevalence of cardiometabolic risk factors in the Atherosclerosis Risk in Communities Study (ARIC) and Fram-
ingham Offspring Study (FOS)
Indicators of cardiometabolic risk
ARIC
% (n)
FOS 
% (n)
Low HDL (<40 mg/dL [male]/<50 mg/dL [female]) 43.0 (4,941) 36.3 (1,259)
Elevated triglycerides (≥150 mg/dL) 34.8 (4,002) 32.2 (1,120)
Impaired fasting glucose (≥100 mg/dL) 49.3 (5,648) 42.1 (1,377)
Elevated fasting glucose (≥126 mg/dL) 11.5 (1,323) 8.7 (286)
Taking diabetic medication 10.5 (1,140) 5.7 (202)
Diabetes* (glucose ≥126 mg/dL and/or on treatment) 16.9 (1,935) 12.8 (421)
Elevated systolic blood pressure (≥130 mm Hg) 41.4 (4,798) 45.0 (1,589)
Elevated diastolic blood pressure (≥85 mm Hg) 9.3 (1,076) 16.2 (573)
Taking blood pressure medication 36.8 (4,241) 28.5 (1,005)
Elevated blood pressure† 57.7 (6,660) 56.8 (2,001)
Large WC (≥80 cm [female]/≥94 cm [male]) 86.4 (10,058) 79.9 (2,761)
Larger WC (>88 cm [female]/>102 cm [male]) 64.8 (7,512) 53.4 (1,844)
*Does not include prior history of diabetes as speciﬁed for the International Diabetes Federation metabolic syndrome deﬁnition.
†Elevated blood pressure is deﬁned by the presence of 1 or more of the following risk factors: systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, and
currently taking antihypertensive medication(s).
HDL, high-density lipoprotein; WC, waist circumference.
Table 4 Observed and predicted prevalence of six cardiometabolic risk clusters in Atherosclerosis Risk in Communities Study (ARIC)
and Framingham Offspring Study (FOS)
Predicted (95% CI) Observed (95% CI)
ARIC population cluster
MetSyn (NCEP ATP III) 51.3 (51.2, 51.4) 52.1 (51.1, 53.0)
MetSyn (IDF) 53.5 (53.4, 53.6) 58.8 (57.9, 59.7)
Abdominal obesity (AO) 63.7 (63.5, 63.9) 65.7 (64.8, 66.5)
AO + diabetes 13.0 (13.0, 13.1) 14.1 (13.5, 14.8)
AO + dyslipidemia 18.9 (18.7, 19.0) 40.8 (39.9, 41.7)
AO + diabetes + dyslipidemia 5.0 (5.0, 5.1) 10.4 (9.8, 11.0)
Demographics
Mean age 62.6
Male (%) 44.2
Non-Hispanic white (%) 77.1
Non-Hispanic African American (%) 23.9
Current smoker (%) 14.9
FOS population cluster
MetSyn (NCEP ATP III) 48.2 (47.9, 48.5) 41.4 (39.7, 43.1)
MetSyn (IDF) 51.4 (51.1, 51.7) 45.8 (44.1, 47.6)
AO 60.1 (59.8, 60.5) 53.8 (52.1, 55.5)
AO + diabetes 9.5 (9.4, 9.7) 8.3 (7.4, 9.3)
AO + dyslipidemia 20.4 (20.1, 20.6) 32.1 (30.4, 33.7)
AO + diabetes + dyslipidemia 4.6 (4.5, 4.6) 6.5 (5.6, 7.3)
Demographics
Mean age 58.8
Male (%) 46.9
Non-Hispanic white (%) 100.0
Non-Hispanic African American (%) 0.0
Current smoker (%) 15.3
CI, conﬁdence interval; IDF, International Diabetes Federation; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III.
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pared with the demographics of the subjects in the
database used for the development of the prediction
model.
Either deﬁnition leads to slightly different preva-
lence estimates that also vary with the population base.
This variation is to be expected as the baseline popu-
lations differ. For example, the ARIC cohort popula-
tion is slightly older, has a greater average waist
circumference, and has a greater number of people
treated for hypertension than the FOS cohort. In addi-
tion, the mean age in both cohorts is greater compared
with the NHANES sample (data not shown). Ford
reported an overall prevalence of metabolic syndrome
based on the IDF deﬁnition of 39% using a sample of
people from across the United States. In contrast, we
report a prevalence of 58.8% in the ARIC cohort and
45.8% in the FOS using the IDF deﬁnition. Our results
illustrate the differences in the base populations and
demonstrate the need to assess prevalence across var-
ious cohorts. One likely explanation for these differ-
ences is the higher mean age in both ARIC and FOS
compared with the NHANES survey. Advancing age is
associated with a greater prevalence of the risk factor
clusters. As illustrated in Table 5, the difference in
the proportion of subjects with metabolic syndrome
among those older than age of 64 years compared with
those younger than 55 years of age was 12% in ARIC,
and 20% in FOS where the mean age in the youngest
group is 48.6 years.
The study is limited because the model utilizes only
factors readily available to most health-care plans.
This, in part, explains the differences between the pre-
dicted and observed prevalence estimates. Another
potential reason is that the cohorts are derived from
data taken for years from 1996 to 1999, whereas the
NHANES data are from 2001 to 2002. Treatment for
dyslipidemia with Hmg_CoA reductase inhibitors
likely increased, which would reduce triglycerides and
increase HDL cholesterol. Treatment with statins is
not considered in the model, so the model likely under-
Table 5 Observed and predicted prevalence of six cardiometabolic risk clusters by age (years) group in Atherosclerosis Risk in
Communities Study (ARIC) and Framingham Offspring Study (FOS)
<55 (N = 604; 5.5%) 55–64 (N = 6007; 54.6%) >64 (N = 4389; 39.9%) 
Predicted
(95% CI)
Observed
(95% CI)
Predicted
(95% CI)
Observed
(95% CI)
Predicted
(95% CI)
Observed 
(95% CI)
ARIC population cluster
MetSyn (NCEP ATP III)
43.7 44.7 48.7 50.0 55.8 55.9
(43.6, 43.9) (40.7, 48.7) (48.7, 48.8) (48.8, 51.3) (55.7, 55.9) (54.4, 57.3)
MetSyn (IDF) 46.1 49.3 51.1 56.9 57.8 62.7
(45.9, 46.4) (45.3, 53.3) (51.0, 51.2) (55.6, 58.1) (57.7, 57.9) (61.2, 64.1)
Abdominal obesity (AO) 61.4 63.6 62.7 66.1 65.4 65.3
(60.7, 62.1) (59.7, 67.4) (62.5, 62.9) (64.9, 67.3) (65.1, 65.7) (63.9, 66.7)
AO + diabetes 9.7 10.8 11.6 13.6 15.5 15.3
(9.5, 10.0) (8.3, 13.2) (11.5, 11.7) (12.8, 14.5) (15.3, 15.6) (14.2, 16.3)
AO + dyslipidemia 15.1 38.7 17.7 40.6 21.0 41.3
(14.6, 15.6) (34.8, 42.6) (17.6, 17.9) (39.4, 41.9) (20.7, 21.2) (39.9, 42.8)
AO + diabetes + dyslipidemia 3.0 7.6 4.2 10.0 6.4 11.3
(2.9, 3.1) (5.5, 9.7) (4.2, 4.3) (9.3, 10.8) (6.4, 6.5) (10.4, 12.3)
Demographics
Mean age 53.9 59.4 68.2
Male (%) 35.8 41.5 47.0
Non-Hispanic white (%) 67.0 76.1 82.1
Non-Hispanic African American (%) 33.1 23.9 17.9
Current smoker (%) 20.2 16.1 11.3
FOS population cluster (N = 1151; 35.7%) (N = 1077; 33.4%) (N = 994; 30.9%)
MetSyn (NCEP ATP III) 39.3 29.2 49.2 46.1 57.5 50.5
(39.0, 39.5) (26.6, 31.8) (49.0, 49.4) (43.1, 49.0) (57.3, 57.6) (47.4, 53.6)
MetSyn (IDF) 43.3 33.0 52.4 50.0 59.8 56.1
(43.0, 43.5) (30.3, 35.7) (52.2, 52.7) (47.1, 53.0) (59.5, 60.0) (53.0, 59.2)
AO 55.0 46.9 60.5 58.9 65.5 56.2
(54.4, 55.6) (44.0, 49.8) (60.0, 61.1) (55.9, 61.8) (65.0, 66.1) (53.1, 59.3)
AO + diabetes 5.5 4.8 9.3 8.1 14.4 12.7
(5.4, 5.6) (3.5, 6.0) (9.3, 9.4) (6.4, 9.7) (14.3, 14.6) (10.6, 14.7)
AO + dyslipidemia 17.5 26.3 20.8 35.8 23.3 34.6
(17.2, 17.9) (23.8, 28.9) (20.4, 21.2) (33.0, 38.7) (22.8, 23.7) (31.6, 37.6)
AO + diabetes + dyslipidemia 2.5 4.2 4.4 5.8 7.1 10.0
(2.4, 2.5) (3.0, 5.3) (4.3, 4.6) (4.4, 7.2) (6.9, 7.2) (8.1, 11.8)
Demographics
Mean age 48.6 59.4 70.4
Male (%) 45.4 48.5 47.6
Non-Hispanic white (%) 100.0 100.0 100.0
Non-Hispanic African American (%) 0.0 0.0 0.0
Current smoker (%) 20.9 14.7 8.9
CI, conﬁdence interval; IDF, International Diabetes Federation; NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III.
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estimates the prevalence of multiple CMR factors. This
results in an underestimation of dyslipidemia in both
ARIC and FOS compared with the observed preva-
lence. The addition of a lipid value while accounting
for lipid lowering treatments would likely improve the
model and could be considered as a second tier screen-
ing prediction model. Prediction models that also
include adjustments for other treatments that may
alter the outcomes such as the use of ACE inhibitors as
well as adherence to prescribed therapies would be of
valued. Unfortunately, many of these variables are not
readily available to most health-care plans but may in
the future.
Age is another key reason for the differences
between the ARIC and FOS prevalence estimates. In
Table 5, the observed and predicted estimates are
closer with advancing age, consistent with the fact that
the risk factors increase with age. In the group
<55 years of age, it is also important to note that the
mean age in FOS is younger, which likely accounts for
the lower observed prevalence. Further investigation
evaluating how various characteristics account for dif-
ferences in sets of multiple CMR factors across varying
populations is needed and is planned for future
analyses.
The advantage of this limited model is applicability
over a wide range of uses, although in certain circum-
stances it may underestimate the true prevalence of
CMR factors. Nevertheless, the addition of a single
clinical variable such as weight or blood pressure
would greatly enhance the accuracy of the model. The
addition could be deployed easily as an initial screen-
ing evaluation and would dictate the need for addi-
tional laboratory testing. Many models include
variables that are often collinear and that actually fail
to provide any added value to the overall accuracy of
the estimates. Such is not the case with the approach
that we took.
As a simple tool for describing the potential at-risk
population in health-care settings, Hollenbeak’s demo-
graphic model provides a ﬁrst step in assessing the
occurrence of CMR factors. Knowing the prevalence
of the CMR factors in their setting, health-care pro-
viders can begin to design and implement cost-effective
and appropriate treatment programs that will result in
improved health and economic outcomes.
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